Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts SYRS Hot Sheet
Join SI Premium – FREE
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
- AptarGroup (ATR) Tops Q1 EPS by 11c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
